Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
It is very uncertain whether inulin and oligofructose 15 g changes withdrawals due to adverse events (9 weeks) compared with inulin and oligofructose 7.5 g daily (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people in remission or with mildly activeulcerative colitis
It is very uncertain whether prebiotics changes withdrawals due to adverse events (4 weeks) compared with probiotics (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people in remission or with mildly activeulcerative colitis
It is very uncertain whether prebiotics changes withdrawals due to adverse events (4 weeks) compared with synbiotics (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotics changes withdrawal due to adverse events (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
GI adverse events · Patients with quiescent ulcerative colitis
Celecoxib showed no clear difference in GI adverse events compared with placebo (low certainty).
1 finding from 1 review
Primary outcome 3: Adverse events · ulceration and other skin changes caused by nerve damage in leprosy
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
Tofacitinib probably leads to lower withdrawals due to adverse events (5 mg/10 mg) compared with placebo (moderate certainty).
1 finding from 1 review
Primary outcome 3: Adverse events · ulceration and other skin changes caused by nerve damage in leprosy
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) changes withdrawal due to adverse events (12 to 52 weeks) compared with 5‐ASA (mesalazine) (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with histologically confirmed diagnosis of ulcerative colitis in remission
It is very uncertain whether prebiotics changes withdrawals due to adverse events (60 days to 6 months) compared with placebo (very low certainty).
1 finding from 1 review
Adverse events · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · Patients with acute pouchitis
It is very uncertain whether metronidazole changes adverse events compared with budesonide enema (very low certainty).
1 finding from 1 review
Adverse events · Patients with acute pouchitis
It is very uncertain whether rifaximin changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Adverse events · Patients with acute pouchitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with chronic pouchitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with chronic pouchitis
It is very uncertain whether bismuth enema changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Adverse events · Patients with chronic pouchitis or ileal pouch‐anal anastomosis
De Simone Formulation showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Adverse events · Patients with ileal pouch‐anal anastomosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with ileal pouch‐anal anastomosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with acute pouchitis
It is very uncertain whether ciprofloxacin changes adverse events compared with metronidazole (very low certainty).
1 finding from 1 review